Skip to main content
. 2018 Apr 11;8:88. doi: 10.3389/fonc.2018.00088

Figure 1.

Figure 1

Systematic treatment stratergies in ALK-positive non-small cell lung cancer (NSCLC) patients. TKI, other ALK tyrosine kinase inhibitor; CT, chemotherapy.